8-K Announcements
6Material company update
May 12, 2026·SEC
Material company update
Mar 18, 2026·SEC
Material company update
Mar 3, 2026·SEC
CalciMedica, Inc.(CALC)Earnings, Financials & Key Ratios
CALC•NASDAQ
$0.79
Price updated Jun 27, 2026
AboutCalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.Show more
- Revenue$0
- EBITDA-$23M+4.4%
- Net Income-$30M-115.8%
- EPS (Diluted)-1.97-61.5%
- ROE-761.02%-526.8%
CALC Price & Volume
CalciMedica, Inc. (CALC) stock price & volume — 10-year historical chart
Loading chart...
Persistent Clinical Burn Erodes Equity Capital Base
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Binary Clinical Trial Failure
"CalciMedica remains a high-risk, pre-revenue biotechnology firm whose valuation is entirely dependent on the success of its CARPO and CRSPA clinical trials. The company faces a precarious financial outlook characterized by a negative equity position of $1.1 million as of 2026Q1 and a consistent quarterly operating burn that frequently exceeds $4.5 million. Investors should remain cautious as the firm's reliance on debt-based financing and the absence of commercial revenue suggest significant dilution risks or potential liquidity crises in the near term."
Verdict Logic
the company's precarious financial position, evidenced by a negative equity balance of $1.1 million and a persistent quarterly cash burn, suggests that the firm lacks the capital runway to reach commercialization without further dilutive financing.
CALC Growth Metrics
CalciMedica, Inc. (CALC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-3.56%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM14.84%
Return on Capital
10 Years-258.92%
5 Years-319.94%
3 Years-503.35%
Last Year-178.41%
CALC Recent Earnings
CalciMedica, Inc. (CALC) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.30-7.1%
$0.28
Rev
—
—
Q2 2026
Mar 3, 2026Metric
Actual
Est
EPS
$0.32+41.8%
$0.55
Rev
—
$33M
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.39+4.9%
$0.41
Rev
—
—
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.40+0.0%
$0.40
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.30vs $0.28-7.1% | — |
| Q2 2026 | Mar 3, 2026 | $0.32vs $0.55+41.8% | —vs $33M |
| Q4 2025 | Nov 12, 2025 | $0.39vs $0.41+4.9% | — |
| Q3 2025 | Aug 12, 2025 | $0.40vs $0.40+0.0% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for CalciMedica, Inc. (CALC)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.79 | $11.84M | -0.40 | — | — | -761.02% | — | |
| $5.00 | $602.98M | -9.43 | -58.19% | -832.58% | -55.89% | — | |
| $38.85 | $7.98B | -14.03 | — | — | -68.16% | — | |
| $327.79 | $9.47B | -24.32 | -100% | — | -43.02% | — | |
| $23.57 | $1.74B | 7.14 | 18.52% | 118.91% | 47.59% | — | |
| $5.55 | $1.36B | -21.35 | 22.09% | -13.58% | -38.11% | — |
Compare CALC vs Peers
CalciMedica, Inc. (CALC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CALC SEC Filings & Documents
CalciMedica, Inc. (CALC) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when CALC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CALC Frequently Asked Questions
CalciMedica, Inc. (CALC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is CALC profitable?
CalciMedica, Inc. (CALC) reported a net loss of $19.5M for fiscal year 2025.
Dividend & Returns
What is CALC's return on equity?
CalciMedica, Inc. (CALC) has a return on equity (ROE) of -761.0%. Negative ROE indicates the company is unprofitable.
What is CalciMedica, Inc.'s free cash flow?
CalciMedica, Inc. (CALC) had negative free cash flow of $21.2M in fiscal year 2025, likely due to heavy capital investments.